Table 2.

Experimental therapeutic prostate cancer vaccines currently in phase II and III clinical trials

Vaccine	Type	Phase	Disease stage	NCT
DCVac	Dendritic-cell vaccine	III	mCRPC	NCT02111577
PROSTVAC	Poxvirus-based vaccine	III II II II	mCRPC Adjuvant therapy BCR Active surveillance	NCT01322490 NCT02772562 NCT02649439 NCT02326805
ProstAtack	Oncolytic virus	III	Curative EBRT Active surveillance	NCT01436968 NCT02768363
ME TARP	Autologous dendritic-cell vaccine targeting TARP	II	BCR	NCT02362451
DC1	Alpha-type-1-polarized dendritic cells with apoptotic allogeneic tumor (LNCap)	II	BCR	NCT00970203
GX301	4 human telomerase reverse transcriptase (hTERT) peptides and 2 adjuvants	II	mCRPC	NCT02293707
mDC/pDC	Tumor peptide-loaded dendritic cells (myeloid, plasmacytoid, and their combination)	II	mCRPC	NCT02692976
ADXS31-142	Live-attenuated strain of Listeria monocytogenes encoding PSA fused to a fragment of the immunostimulant listeriolysin O protein	I/II	mCRPC	NCT02325557
DC vaccine	Autologous dendritic cells with mRNA from primary prostate cancer tissue, hTERT, and survivin	I/II	Adjuvant, high risk of PSA relapse	NCT01197625
Ad5-SGE-REIC/Dkk-3	Recombinant adenovirus designed to increase intracellular production of REIC protein	I/II	Localized prostate cancer	NCT01931046

EBRT: external beam radiation therapy; mCRPC: metastatic castration-resistant prostate cancer; BCR: biochemical recurrence (PSA-only disease)